We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000488
First Posted: October 28, 1999
Last Update Posted: April 14, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
  Purpose

To determine whether reduction of cholesterol by drug therapy significantly lowered the atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise healthy men.

Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a year-by-year breakdown.


Condition Intervention Phase
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Drug: cholestyramine Behavioral: diet, fat-restricted Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: June 1973
Study Completion Date: October 1989
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 59 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Men, ages 35-59. Type II hyperlipoproteinemia. Free from coronary heart disease.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000488


Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
OverallOfficial: Francois Abboud University of Iowa
OverallOfficial: Elizabeth Barrett-Connor University of California, San Diego
OverallOfficial: Reagan Bradford Oklahoma Medical Research Foundation
OverallOfficial: Marilyn Buzzard University of Minnesota - Clinical and Translational Science Institute
OverallOfficial: Gerald Cooper Centers for Disease Control and Prevention
OverallOfficial: John Farquhar Stanford University
OverallOfficial: Ivan Frantz University of Minnesota - Clinical and Translational Science Institute
OverallOfficial: Anne Goldberg Washington University School of Medicine
OverallOfficial: Frank Ibbott Bio-Science Laboratories
OverallOfficial: William, Insull Baylor College of Medicine
OverallOfficial: Robert Knoop University of Washington
OverallOfficial: Peter Kwiterovich Johns Hopkins University
OverallOfficial: John LaRosa George Washington University
OverallOfficial: J. Little University of Toronto
OverallOfficial: L. Sheffield University of Alabama at Birmingham
OverallOfficial: Dennis Sprecher University of Cincinnati
  More Information

Publications:
Rifkind B, Goor R: The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT). Drugs Affecting Lipid Metabolism, l5l-l57, Fumagalli R, Kritchevsky D, Paoletti R (Eds): Elsevier/North-Holland Biomedical Press, l980.
Knopp RH: Test of the Lipid Hypothesis: The Coronary Primary Prevention Trial (CPPT) of the Lipid Research Clinics Program. Proceedings of the Fifth International Symposium on Atherosclerosis, 509-512, Gotto, AM, Jr. (Ed.): Springer-Verlag, 1980.
Rifkind BM: The Lipid Research Clinics Coronary Primary Prevention Trial (CPPT). Heartbeat, 1:7-8, 1985.
Rifkind BM: The Lipid Research Clinics Coronary Primary Prevention Trial. In Shepherd G, et al (Eds). Lipoproteins and Coronary Heart Disease. London and Glasgow. Blantyre Printing Ltd.:109, 1986.
Brook JG, Rifkind BM: The Lipid Research Clinics Primary Prevention Trial and its Aftermath. In: Recent Aspects of Diagnosis and Treatment of Lipoprotein Disorders: Impact on Prevention of Atherosclerotic Disease. Alan R Liss Inc., 7-14, 1988.

Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: LRC-CPPT
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.

ClinicalTrials.gov Identifier: NCT00000488     History of Changes
Other Study ID Numbers: 7
First Submitted: October 27, 1999
First Posted: October 28, 1999
Last Update Posted: April 14, 2016
Last Verified: April 2012

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Ischemia
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Pathologic Processes
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Cholestyramine Resin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents